IL1B and type 2 diabetes mellitus: PCSK9 inhibitors were found to alleviate cognitive dysfunction in type 2 diabetes mellitus (T2DM) rats by reducing the expression of PCSK9, IL-1β, IL-6, and TNF-α while increasing LDLR expression in hippocampal tissues [159].